Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Valeria MerzDavide Melisi

Abstract

Pancreatic cancer is one of the most lethal solid tumors, mainly because of its intrinsic chemoresistance. We identified TAK1 as a central hub sustaining this resistance. Nanoliposomal irinotecan (nal-IRI) is a novel treatment for metastatic gemcitabine-refractory pancreatic cancer. We endeavored to identify circulating markers for TAK1 activation predicting chemoresistance in this setting. In vivo activity of nal-IRI was validated in an orthotopic nude murine model expressing TAK1-specific shRNA. Plasma concentration of 20 different cytokines were measured by a multiplex xMAP/Luminex technology in patients prospectively enrolled to receive nal-IRI plus 5-fluorouracil/leucovorin (5-FU/LV). The optimal cutoff thresholds able to significantly predict patients' outcome were obtained on the basis of the maximization of the Youden's statistics. Differential expression profiling revealed the gene coding for IL8 as the most significantly downregulated in shTAK1 pancreatic cancer cell lines. Mice bearing shTAK1 tumors had significantly lower plasma levels of IL8 and experienced a significant reduction in tumor growth if treated with nal-IRI, whereas those bearing TAK1-proficient tumors were resistant to this agent. In a discovery cohor...Continue Reading

References

Jan 19, 2000·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·Q ShiK Xie
Jan 1, 1950·Cancer·W J YOUDEN
Jan 18, 2007·Expert Opinion on Therapeutic Targets·Davide Melisi, Paul J Chiao
Oct 8, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Davide MelisiPaul J Chiao
Jul 9, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Carmine CarboneDavide Melisi
Jul 12, 2011·Journal of the National Cancer Institute·Davide MelisiPaul J Chiao
Mar 27, 2012·Expert Opinion on Therapeutic Targets·Carmine Carbone, Davide Melisi
Jul 2, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Helmut OettleUwe Pelzer
Oct 25, 2014·Current Pharmaceutical Design·Davide MelisiGiampaolo Tortora
Oct 27, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Zhuo-Nan ZhuangPaul J Chiao
Sep 14, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sharlene GillMalcolm Moore
Mar 17, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Carmine CarboneDavide Melisi
Jun 13, 2017·Critical Reviews in Oncology/hematology·Giuseppe AprileMario Scartozzi
Sep 4, 2017·Cancer Treatment Reviews·Carlos AlfaroIgnacio Melero
Nov 18, 2017·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Raffaela SantoroDavide Melisi
Nov 21, 2018·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Richard A HubnerJens T Siveke
Sep 29, 2019·Molecular Cancer Therapeutics·Raffaela SantoroDavide Melisi

❮ Previous
Next ❯

Citations

Mar 30, 2021·Frontiers in Oncology·Valeria MerzDavide Melisi
Apr 4, 2021·Cancer Treatment Reviews·Sara De DossoMarkus Borner
Jun 29, 2021·Cellular and Molecular Gastroenterology and Hepatology·Silvia Pietrobono, Davide Melisi
Aug 28, 2021·Cancers·Fabio SabbadiniDavide Melisi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.